These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33353145)

  • 1. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma.
    Spahn S; Roessler D; Pompilia R; Gabernet G; Gladstone BP; Horger M; Biskup S; Feldhahn M; Nahnsen S; Hilke FJ; Scheiner B; Dufour JF; De Toni EN; Pinter M; Malek NP; Bitzer M
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
    Chen KY; Popovic A; Hsiehchen D; Baretti M; Griffith P; Bista R; Baghdadi A; Kamel IR; Simon SM; Migler RD; Yarchoan M
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
    J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
    Fessas P; Naeem M; Pinter M; Marron TU; Szafron D; Balcar L; Saeed A; Jun T; Dharmapuri S; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; Nishida N; Kudo M; Kaseb A; Huang YH; Ang C; Pillai A; Rimassa L; Naqash AR; Sharon E; Cortellini A; Pinato DJ
    Liver Cancer; 2021 Nov; 10(6):583-592. PubMed ID: 34950181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
    Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Lee S; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
    J Hepatocell Carcinoma; 2015; 2():39-47. PubMed ID: 27508193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.
    Cowzer D; Chou JF; Walch H; Keane F; Khalil D; Shia J; Do RKG; Yarmohammadi H; Erinjeri JP; El Dika I; Yaqubie A; Azhari H; Gambarin M; Hajj C; Crane C; Wei AC; Jarnagin W; Solit DB; Berger MF; O'Reilly EM; Schultz N; Chatila W; Capanu M; Abou-Alfa GK; Harding JJ
    Oncologist; 2024 Jun; ():. PubMed ID: 38937977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.
    Sobirey R; Matuschewski N; Gross M; Lin M; Kao T; Kasolowsky V; Strazzabosco M; Stein S; Savic LJ; Gebauer B; Jaffe A; Duncan J; Madoff DC; Chapiro J
    Eur Radiol; 2024 Jul; ():. PubMed ID: 39033181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
    Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
    Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.